Clinical Trial Detail

NCT ID NCT02531932
Title Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Amy Tiersten
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin

Everolimus

Age Groups: adult

Additional content available in CKB BOOST